A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 154, Issue 2, 1996, Pages 324-328

  Leblanc, Pierre ^a   Knight, Allan ^b   Kreisman, Harvey ^b   Borkhoff, Cornelia M ^b   Johnston, Patrick R ^b  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SALBUTAMOL; SALMETEROL;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CIRCADIAN RHYTHM; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FLOWMETER; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; SLEEP DISORDER;

EID: 0029775788     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.154.2.8756801     Document Type: Article

References (15)

1. National Heart, Lung, and Blood Institute, National Institutes of Health. 1992. International consensus report on diagnosis and treatment of asthma. Eur. Respir. J. 5:601-641.
2. Kerrebijn, K. F. 1991. Beta agonists. In M. A. Kaliner, P. J. Barnes, and C. G. A. Persson, editors. Lung Biology in Health and Disease, Vol. 39: Asthma: its pathology and treatment. Marcel Dekker, New York. 523-558.
3. Malo, J. L., H. Ghezzo, C. Trudeau, J. L'Archevêque, and A. Cartier. 1992. Salmeterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J. Allergy Clin. Immunol. 89:567-574.
4. Newnham, D. M., C. G. Ingram, J. Earnshaw, J. B. D. Palmer, and D. P. Dhillon. 1993. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir. Med. 87:439-444.
5. Twentyman, O. P., J. P. Finnerty, A. Harris, J. Palmer, and S. T. Holgate. 1990. Protection against allergen-induced asthma by salmeterol. Lancet 336:1338-1342.
6. Ullman, A., and N. Svedmyr. 1988. Salmeterol, a new long acting inhaled β adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 43:674-678.
7. Dahl, R., J. Earnshaw, and J. B. D. Palmer. 1991. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur. Respir. J. 4:1178-1184.
8. Pearlman, D. S., P. Chervinsky, C. La Force, J. M. Seltzer, D. L. Southern, J. P. Kemp, R. J. Dockhorn, J. Grossman, R. F. Liddle, S. W. Yancey, D. M. Cocchetto, W. J. Alexander, and A. Van As. 1992. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N. Engl. J. Med. 327:1420-1425.
9. Britton, M. G., J. S. Earnshaw, and J. B. D. Palmer. 1992. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur. Respir. J. 5:1062-1067.
10. 2 agonist. B.M.J. 301:1365-1368.
11. Quanjer, P. H., editor. 1983. Report of Working Party, European Community for Coal and Steel. Standardized lung function testing: standardization of lung function tests. Bull. Eur. Physiopathol. Respir. 19(Suppl. 5):7-87.
12. ® Users Guide. Version 6, 4th ed. SAS Institute Inc., Cary, NC.
13. Gail, M., and R. Simon. 1985. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372.
14. Greening, A. P., P. W. Ind, M. Northfield, and G. Shaw. 1994. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344:219-224.
15. Woolcock, A. 1994. Effect of the addition of salmeterol versus doubling the dose of inhaled steroid in asthmatics. Eur. Respir. J. 7 (Suppl. 18):365S.